News
11don MSN
Vaccinating young children against Covid-19 may be more challenging this respiratory virus season
Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...
As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...
Coronavirus infections are climbing again, marking another summer wave as children go back to school. But this uptick arrives ...
6d
Daily Express US on MSNPfizer's Covid-19 vaccine availability for children under 5 faces potential FDA roadblock
The landscape of COVID-19 vaccinations for children is shifting in the US. How will this affect the upcoming virus season?
The Canadian Press on MSN1d
Health Canada approves updated Pfizer, Moderna COVID-19 vaccines for fall
TORONTO — Health Canada has authorized updated COVID-19 vaccines by Pfizer and BioNTech and by Moderna for use this ...
A third dose of the Pfizer COVID-19 vaccine can "strongly" boost protection against the delta variant, suggests new data released by Pfizer.
Pfizer also said it is working to improve its existing vaccine formulation, developed jointly with Germany's BioNTech, based on the vaccine's reaction to new COVID-19 variants that arise.
People with weakened immune systems who received the Pfizer or Moderna vaccines can also get their third dose of a COVID-19 vaccine if it's been at least four weeks since the second dose (and if ...
London — U.S. drugmaker Pfizer said Monday that human trials suggest its coronavirus vaccine is 90% effective at preventing COVID-19 infections in people not known to have had the virus already.
The US Centers for Disease Control and Prevention updated its recommendations for the Pfizer/BioNTech Covid-19 vaccine booster on Wednesday to include children as young as 12, at least five months ...
Pfizer’s clinical trials in children 5 to 11 did not measure the vaccine’s effectiveness against COVID-19. Effectiveness was “never the intended primary endpoint,” Anderson said.
A technician inspects vials of coronavirus disease (COVID-19) vaccine candidate BNT162b2 at a Pfizer manufacturing site in manufacturing site in St. Louis, Missouri, U.S. in an undated photograph.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results